Affordable Access

Access to the full text

Recent advances in osteoclast biology

Authors
  • Ono, Takehito1, 2
  • Nakashima, Tomoki1, 2
  • 1 Tokyo Medical and Dental University (TMDU), Department of Cell Signaling, Graduate School of Medical and Dental Sciences, Yushima 1-5-45, Bunkyo-ku, Tokyo, 113-8549, Japan , Tokyo (Japan)
  • 2 Japan Agency for Medical Research and Development (AMED), Core Research for Evolutional Science and Technology (CREST), Yushima 1-5-45, Bunkyo-ku, Tokyo, 113-8549, Japan , Tokyo (Japan)
Type
Published Article
Journal
Histochemistry and Cell Biology
Publisher
Springer Berlin Heidelberg
Publication Date
Feb 01, 2018
Volume
149
Issue
4
Pages
325–341
Identifiers
DOI: 10.1007/s00418-018-1636-2
Source
Springer Nature
Keywords
License
Yellow

Abstract

The bone is an essential organ for locomotion and protection of the body, as well as hematopoiesis and mineral homeostasis. In order to exert these functions throughout life, bone tissue undergoes a repeating cycle of osteoclastic bone resorption and osteoblastic bone formation. The osteoclast is a large, multinucleated cell that is differentiated from monocyte/macrophage lineage cells by macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL). RANKL transduces its signal through the signaling receptor, RANK. RANKL/RANK signaling activates NFATc1, the master regulator of osteoclastogenesis, to induce osteoclastogenic gene expression. Many types of cells express RANKL to support osteoclastogenesis depending on the biological context and the dysregulation of RANKL signaling leads to bone diseases such as osteoporosis and osteopetrosis. This review outlines the findings on osteoclast and RANKL/RANK signaling that have accumulated to date.

Report this publication

Statistics

Seen <100 times